Dynavax Technologies Corporation (0IDA.L)
USD 12.75
(-1.43%)
USD 12.75
(-1.43%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 53.29 Million USD | -10.36% |
| 2022 | 59.44 Million USD | -3.08% |
| 2021 | 61.33 Million USD | -3.7% |
| 2020 | 63.68 Million USD | 54.09% |
| 2019 | 41.33 Million USD | 117.29% |
| 2018 | 19.02 Million USD | 5996.79% |
| 2017 | 312 Thousand USD | 103.81% |
| 2016 | -8.18 Million USD | -114.18% |
| 2015 | -3.82 Million USD | 20.15% |
| 2014 | -4.78 Million USD | 0.0% |
| 2013 | - USD | 100.0% |
| 2012 | -3.05 Million USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | -100.0% |
| 2007 | 6.45 Million USD | 2412.45% |
| 2006 | 257 Thousand USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 61.8 Million USD | 15.98% |
| 2024 Q2 | 62.46 Million USD | 1.06% |
| 2023 Q3 | 49.41 Million USD | -6.92% |
| 2023 Q2 | 53.08 Million USD | -7.98% |
| 2023 Q1 | 57.69 Million USD | -2.95% |
| 2023 Q4 | 53.29 Million USD | 7.85% |
| 2023 FY | 53.29 Million USD | -10.36% |
| 2022 Q4 | 59.44 Million USD | -42.07% |
| 2022 FY | 59.44 Million USD | -3.08% |
| 2022 Q2 | 73.97 Million USD | -6.4% |
| 2022 Q3 | 102.6 Million USD | 38.7% |
| 2022 Q1 | 79.03 Million USD | 28.86% |
| 2021 Q4 | 61.33 Million USD | -8.86% |
| 2021 FY | 61.33 Million USD | -3.7% |
| 2021 Q2 | 86.45 Million USD | 25.57% |
| 2021 Q1 | 68.84 Million USD | 8.1% |
| 2021 Q3 | 67.29 Million USD | -22.16% |
| 2020 FY | 63.68 Million USD | 54.09% |
| 2020 Q2 | 54.39 Million USD | 13.08% |
| 2020 Q3 | 59.03 Million USD | 8.53% |
| 2020 Q4 | 63.68 Million USD | 7.89% |
| 2020 Q1 | 48.09 Million USD | 16.37% |
| 2019 Q3 | 39.35 Million USD | 7.44% |
| 2019 Q2 | 36.62 Million USD | 32.86% |
| 2019 Q1 | 27.56 Million USD | 44.93% |
| 2019 FY | 41.33 Million USD | 117.29% |
| 2019 Q4 | 41.33 Million USD | 5.02% |
| 2018 FY | 19.02 Million USD | 5996.79% |
| 2018 Q1 | 550 Thousand USD | 76.28% |
| 2018 Q2 | 5.11 Million USD | 829.45% |
| 2018 Q4 | 19.02 Million USD | 52.76% |
| 2018 Q3 | 12.45 Million USD | 143.58% |
| 2017 Q4 | 312 Thousand USD | 0.0% |
| 2017 FY | 312 Thousand USD | 103.81% |
| 2017 Q3 | - USD | 100.0% |
| 2017 Q2 | -5.24 Million USD | 0.0% |
| 2017 Q1 | - USD | 100.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | -8.18 Million USD | 0.0% |
| 2016 FY | -8.18 Million USD | -114.18% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 100.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | -3.82 Million USD | 0.0% |
| 2015 FY | -3.82 Million USD | 20.15% |
| 2015 Q1 | - USD | 100.0% |
| 2015 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | -4.78 Million USD | 0.0% |
| 2014 Q4 | -4.78 Million USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 100.0% |
| 2013 Q1 | -2.76 Million USD | 9.58% |
| 2013 Q2 | -3.26 Million USD | -18.16% |
| 2013 Q3 | -3.27 Million USD | -0.4% |
| 2013 Q4 | - USD | 100.0% |
| 2012 FY | -3.05 Million USD | 0.0% |
| 2012 Q2 | -5.42 Million USD | 0.0% |
| 2012 Q3 | - USD | 100.0% |
| 2012 Q4 | -3.05 Million USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q2 | -2.92 Million USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 100.0% |
| 2010 Q1 | -2.61 Million USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 100.0% |
| 2010 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 FY | - USD | -100.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | -100.0% |
| 2008 Q2 | 5.83 Million USD | 0.0% |
| 2008 Q1 | - USD | -100.0% |
| 2007 Q3 | 263 Thousand USD | 6.05% |
| 2007 Q1 | 246 Thousand USD | -4.28% |
| 2007 Q2 | 248 Thousand USD | 0.81% |
| 2007 FY | 6.45 Million USD | 2412.45% |
| 2007 Q4 | 6.45 Million USD | 2355.13% |
| 2006 Q3 | 1.52 Million USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | 257 Thousand USD | 0.0% |
| 2006 Q4 | 257 Thousand USD | -83.15% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -343.197% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -179.356% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | 10.731% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -449.042% |
| bluebird bio, Inc. | 22.91 Million USD | -132.515% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -1789.046% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | 86.189% |
| Myriad Genetics, Inc. | 20.1 Million USD | -165.124% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -39.138% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 31.157% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.359% |
| Waters Corporation | 516.23 Million USD | 89.677% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 98.953% |
| Biogen Inc. | 2.52 Billion USD | 97.892% |
| Nektar Therapeutics | 16.1 Million USD | -230.973% |
| Perrigo Company plc | 1.14 Billion USD | 95.329% |
| Illumina, Inc. | 587 Million USD | 90.922% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -413.787% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -26.55% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 95.187% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -384.543% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 97.935% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 18.794% |
| FibroGen, Inc. | 41.56 Million USD | -28.209% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 94.831% |
| OPKO Health, Inc. | 65.69 Million USD | 18.885% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 40.222% |
| Exelixis, Inc. | 17.32 Million USD | -207.626% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 97.922% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -252.098% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 2280.442% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 92.787% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -87.476% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | 83.494% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -589.392% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | 58.237% |
| Blueprint Medicines Corporation | 21.22 Million USD | -151.096% |
| Insmed Incorporated | 83.24 Million USD | 35.986% |
| TG Therapeutics, Inc. | 39.82 Million USD | -33.817% |
| Incyte Corporation | 62.97 Million USD | 15.375% |
| Emergent BioSolutions Inc. | 328.9 Million USD | 83.798% |